Back to Authors

Crotti, Lia

https://orcid.org/0000-0001-8739-6527

Mayo Clinic

IRCCS Istituto Auxologico Italiano

Citations 23

Characterization of SEMA3A -Encoded Semaphorin as a Naturally Occurring K v 4.3 Protein Inhibitor and its Contribution to Brugada Syndrome
Boczek, Nicole J. , Ye, Dan , Johnson, Eric K. , Wang, Wei , Crotti, Lia , Tester, David J. , Dagradi, Federica , Mizusawa, Yuka , Torchio, Margherita , Alders, Mariëlle , Giudicessi, John R. , Wilde, Arthur A.M. , Schwartz, Peter J. , Nerbonne, Jeanne M. , Ackerman, Michael J. , Crotti, Lia , Schwartz, Peter J. , Dagradi, Federica

Circulation Research | June 25, 2014 | Volume: 115 | Issue: 4 | Pages: 460-469

10.1161/circresaha.115.303657 Get It

Rationale : Semaphorin 3A ( SEMA3A )-encoded semaphorin is a chemorepellent that disrupts neural patterning in the nervous and cardiac systems. In addition, SEMA3A has an amino acid motif that is analogous to hanatoxin, an inhibitor of voltage-gated K + channels. SEMA3A -knockout mice exhibit an abnormal ECG pattern and are prone to ventricular arrhythmias and sudden cardiac death. Objective : Our aim was to determine whether SEMA3A is a naturally occurring protein inhibitor of K v 4.3 (I to ) channels and its potential contribution to Brugada syndrome. Methods and Results : K v 4.3, Na v 1.5, Ca v 1.2, or K v 4.2 were coexpressed or perfused with SEMA3A in HEK293 cells, and electrophysiological properties were examined via whole-cell patch clamp technique. SEMA3A selectively altered K v 4.3 by significantly reducing peak current density without perturbing K v 4.3 cell surface protein expression. SEMA3A also reduced I to current density in cardiomyocytes derived from human-induced pluripotent stem cells. Disruption of a putative toxin binding domain on K v 4.3 was used to assess physical interactions between SEMA3A and K v 4.3. These findings in combination with coimmunoprecipitations of SEMA3A and K v 4.3 revealed a potential direct binding interaction between these proteins. Comprehensive mutational analysis of SEMA3A was performed on 198 unrelated SCN5A genotype–negative patients with Brugada syndrome, and 2 rare SEMA3A missense mutations were identified. The SEMA3A mutations disrupted SEMA3A’s ability to inhibit K v 4.3 channels, resulting in a significant gain of K v 4.3 current compared with wild-type SEMA3A. Conclusions : This study is the first to demonstrate SEMA3A as a naturally occurring protein that selectively inhibits K v 4.3 and SEMA3A as a possible Brugada syndrome susceptibility gene through a K v 4.3 gain-of-function mechanism.
A Novel Disease Gene for Brugada Syndrome
Ishikawa, Taisuke , Marcou, Cherisse A. , Tester, David J. , Ackerman, Michael J. , Crotti, Lia , Schwartz, Peter J. , Park, Jeong-Euy, Nakamura, Kazufumi , Hiraoka, Masayasu , Nakazawa, Kiyoshi, Sakurada, Harumizu, Arimura, Takuro , Makita, Naomasa , Ishikawa, Taisuke , Sato, Akinori , Crotti, Lia , Schwartz, Peter J. , On, Young Keun , Makita, Naomasa , Kimura, Akinori

Circulation: Arrhythmia and Electrophysiology | October 13, 2012 | Volume: 5 | Issue: 6 | Pages: 1098-1107

10.1161/circep.111.969972 Get It

Background— Mutations in genes including SCN5A encoding the α-subunit of the cardiac sodium channel (hNav1.5) cause Brugada syndrome via altered function of cardiac ion channels, but more than two-thirds of Brugada syndrome remains pathogenetically elusive. T-tubules and sarcoplasmic reticulum are essential in excitation of cardiomyocytes, and sarcolemmal membrane-associated protein (SLMAP) is a protein of unknown function localizing at T-tubules and sarcoplasmic reticulum. Methods and Results— We analyzed 190 unrelated Brugada syndrome patients for mutations in SLMAP . Two missense mutations, Val269Ile and Glu710Ala, were found in heterozygous state in 2 patients but were not found in healthy individuals. Membrane surface expression of hNav1.5 in the transfected cells was affected by the mutations, and silencing of mutant SLMAP by small interfering RNA rescued the surface expression of hNav1.5. Whole-cell patch-clamp recordings of hNav1.5-expressing cells transfected with mutant SLMAP confirmed the reduced hNav1.5 current. Conclusions— The mutations in SLMAP may cause Brugada syndrome via modulating the intracellular trafficking of hNav1.5 channel.